BACKGROUND: Recombinant factor VIIa (rFVIIa) is licensed for use in patients with haemophilia and inhibitory allo-antibodies. It is also increasingly being used for off-license indications to prevent bleeding in operations where blood loss is likely to be high, and/or to stop bleeding that is proving difficult to control by other means.
Simpson, E., Lin, Y., Stanworth, S., Birchall, J., Doree, C., & Hyde, C. (2012). Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd005011.pub4